W.H. van der Laan

1.3k total citations
28 papers, 751 citations indexed

About

W.H. van der Laan is a scholar working on Rheumatology, Surgery and Pharmacology. According to data from OpenAlex, W.H. van der Laan has authored 28 papers receiving a total of 751 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Rheumatology, 5 papers in Surgery and 5 papers in Pharmacology. Recurrent topics in W.H. van der Laan's work include Rheumatoid Arthritis Research and Therapies (15 papers), Osteoarthritis Treatment and Mechanisms (10 papers) and Total Knee Arthroplasty Outcomes (5 papers). W.H. van der Laan is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (15 papers), Osteoarthritis Treatment and Mechanisms (10 papers) and Total Knee Arthroplasty Outcomes (5 papers). W.H. van der Laan collaborates with scholars based in Netherlands, United States and Germany. W.H. van der Laan's co-authors include Bart J. F. van den Bemt, C.H.M. van den Ende, Thomas Pap, F.H.J. van den Hoogen, Alfons A den Broeder, Henk Schers, Rinie Geenen, Johanna E Vriezekolk, J.H. Verheijen and Steffen Gay and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Annals of the Rheumatic Diseases.

In The Last Decade

W.H. van der Laan

28 papers receiving 734 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
W.H. van der Laan Netherlands	15	322	168	126	101	99	28	751
Gülsüm Emel Pamuk Türkiye	18	185 0.6×	200 1.2×	212 1.7×	48 0.5×	131 1.3×	65	984
Fernando Pimentel‐Santos Portugal	17	601 1.9×	345 2.1×	160 1.3×	47 0.5×	58 0.6×	73	942
Marc Scherlinger France	16	274 0.9×	401 2.4×	136 1.1×	24 0.2×	50 0.5×	40	910
Steven C. Hoffmann United States	9	210 0.7×	181 1.1×	114 0.9×	37 0.4×	154 1.6×	11	676
Henri A. Ménard Canada	17	1.1k 3.3×	272 1.6×	126 1.0×	29 0.3×	39 0.4×	33	1.5k
Jelena Vojinović Serbia	15	299 0.9×	207 1.2×	308 2.4×	57 0.6×	135 1.4×	54	1.1k
A.J. Lehman Canada	12	765 2.4×	212 1.3×	114 0.9×	14 0.1×	94 0.9×	30	1.2k
Shi‐Yang Guan China	17	258 0.8×	205 1.2×	159 1.3×	112 1.1×	42 0.4×	46	769
Moraye B. Bear United States	10	420 1.3×	209 1.2×	156 1.2×	23 0.2×	48 0.5×	16	1.1k
Toby Garrood United Kingdom	14	608 1.9×	420 2.5×	133 1.1×	28 0.3×	56 0.6×	36	1.1k

Countries citing papers authored by W.H. van der Laan

Since Specialization

Citations

This map shows the geographic impact of W.H. van der Laan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W.H. van der Laan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W.H. van der Laan more than expected).

Fields of papers citing papers by W.H. van der Laan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W.H. van der Laan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W.H. van der Laan. The network helps show where W.H. van der Laan may publish in the future.

Co-authorship network of co-authors of W.H. van der Laan

This figure shows the co-authorship network connecting the top 25 collaborators of W.H. van der Laan. A scholar is included among the top collaborators of W.H. van der Laan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W.H. van der Laan. W.H. van der Laan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Verhoef, Lise M, Nathan den Broeder, Rogier M. Thurlings, et al.. (2019). LB0010 ULTRA-LOW DOSES OF RITUXIMAB OR RETREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL. Annals of the Rheumatic Diseases. 78. 264–265. 1 indexed citations

Verhoef, Lise M, Nathan den Broeder, Rogier M. Thurlings, et al.. (2019). Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial. The Lancet Rheumatology. 1(3). e145–e153. 23 indexed citations

Schers, Henk, Sander Koëter, W.H. van der Laan, et al.. (2018). Preliminary effects of a regional approached multidisciplinary educational program on healthcare utilization in patients with hip or knee osteoarthritis: an observational study. BMC Family Practice. 19(1). 82–82. 14 indexed citations

Vriezekolk, Johanna E, Henk Schers, Marc W. Nijhof, et al.. (2017). Development of the “Treatment beliefs in knee and hip OsteoArthritis (TOA)” questionnaire. BMC Musculoskeletal Disorders. 18(1). 402–402. 18 indexed citations

Geenen, Rinie, Henk Schers, F.H.J. van den Hoogen, et al.. (2017). Treatment Beliefs Underlying Intended Treatment Choices in Knee and Hip Osteoarthritis. International Journal of Behavioral Medicine. 25(2). 198–206. 8 indexed citations

Tweehuysen, Lieke, Bart J. F. van den Bemt, Alphons J.L. de Jong, et al.. (2017). Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab. Arthritis & Rheumatology. 70(1). 60–68. 115 indexed citations

Pasma, Annelieke, Reinier Timman, Adriaan van ’t Spijker, et al.. (2017). Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?. PLoS ONE. 12(2). e0171070–e0171070. 27 indexed citations

Pasma, Annelieke, Johanna M. W. Hazes, Jan J.V. Busschbach, et al.. (2016). Psychosocial predictors of DMARD adherence in the first three months of treatment for early arthritis. Patient Education and Counseling. 100(1). 126–132. 2 indexed citations

Vriezekolk, Johanna E, Rinie Geenen, W.H. van der Laan, et al.. (2016). Reasons for treatment choices in knee and hip osteoarthritis: a qualitative study. Osteoarthritis and Cartilage. 24. S489–S489. 1 indexed citations

10.

Pasma, Annelieke, J. M. W. Hazes, Jan J.V. Busschbach, et al.. (2016). OP0197-HPR Psychosocial Predictors of DMARD Adherence in The First Three Months of Treatment for Early Arthritis. Annals of the Rheumatic Diseases. 75. 131–131. 1 indexed citations

11.

Geenen, Rinie, W.H. van der Laan, Henk Schers, et al.. (2016). Hierarchical structure and importance of patients’ reasons for treatment choices in knee and hip osteoarthritis: a concept mapping study. Lara D. Veeken. 56(2). 271–278. 13 indexed citations

12.

Pasma, Annelieke, Reinier Timman, Jan J.V. Busschbach, et al.. (2015). Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease. Arthritis Research & Therapy. 17(1). 281–281. 51 indexed citations

13.

Drynda, Andreas, Paul H.A. Quax, Manfred Neumann, et al.. (2005). Gene Transfer of Tissue Inhibitor of Metalloproteinases-3 Reverses the Inhibitory Effects of TNF-α on Fas-Induced Apoptosis in Rheumatoid Arthritis Synovial Fibroblasts. The Journal of Immunology. 174(10). 6524–6531. 44 indexed citations

14.

Laan, W.H. van der, Paul H.A. Quax, Christian A. Seemayer, et al.. (2003). Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Therapy. 10(3). 234–242. 88 indexed citations

15.

Ronday, H. K., W.H. van der Laan, Paul P. Tak, et al.. (2001). Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis. Lara D. Veeken. 40(1). 55–61. 73 indexed citations

16.

Verhoeven, Arco C., Maarten Boers, J.M. te Koppele, et al.. (2001). Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high‐dose prednisolone. Lara D. Veeken. 40(11). 1231–1237. 23 indexed citations

17.

Laan, W.H. van der, et al.. (2000). Lack of effect of doxyxyxline on disease activity and pyridinoline excretion rates in rheumatoid arthritis : a double-blind placebo-controlled study: abstract. Annals of the Rheumatic Diseases. 59. 156. 1 indexed citations

18.

Pap, Thomas, W.H. van der Laan, Karlfried R. Aupperle, et al.. (2000). Modulation of fibroblast-mediated cartilage degradation by articular chondrocytes in rheumatoid arthritis. Arthritis & Rheumatism. 43(11). 2531–2536. 52 indexed citations

19.

Laan, W.H. van der, Thomas Pap, H. K. Ronday, et al.. (2000). Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of a cell surface-targeted plasmin inhibitor. Arthritis & Rheumatism. 43(8). 1710–1718. 42 indexed citations

20.

Laan, W.H. van der, et al.. (1996). Therapeutic Suggestion Has No Effect on Postoperative Morphine Requirements. Anesthesia & Analgesia. 82(1). 148–152. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact